Literature DB >> 16622217

Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Maija Toropainen1, Leena Saarinen, Gestur Vidarsson, Helena Käyhty.   

Abstract

The relative contributions of antibody-induced complement-mediated bacterial lysis and antibody/complement-mediated phagocytosis to host immunity against meningococcal infections are currently unclear. Further, the in vivo effector functions of antibodies may vary depending on their specificity and Fc heavy-chain isotype. In this study, a mouse immunoglobulin G2a (mIgG2a) monoclonal antibody (MN12H2) to meningococcal outer membrane protein PorA (P1.16), its human IgG subclass derivatives (hIgG1 to hIgG4), and an mIgG2a monoclonal antibody (Nmb735) to serogroup B capsular polysaccharide (B-PS) were evaluated for passive protection against meningococcal serogroup B strain 44/76-SL (B:15:P1.7,16) in an infant rat infection model. Complement component C6-deficient (PVG/c-) rats were used to assess the importance of complement-mediated bacterial lysis for protection. The PorA-specific parental mIgG2a and the hIgG1 to hIgG3 derivatives all induced efficient bactericidal activity in vitro in the presence of human or infant rat complement and augmented bacterial clearance in complement-sufficient HsdBrlHan:WIST rats, while the hIgG4 was unable to do so. In C6-deficient PVG/c- rats, lacking complement-mediated bacterial lysis, the augmentation of bacterial clearance by PorA-specific mIgG2a and hIgG1 antibodies was impaired compared to that in the syngeneic complement-sufficient PVG/c+ rat strain. This was in contrast to the case for B-PS-specific mIgG2a, which conferred similar protective activity in both rat strains. These data suggest that while anti-B-PS antibody can provide protection in the infant rats without membrane attack complex formation, the protection afforded by anti-PorA antibody is more dependent on the activation of the whole complement pathway and subsequent bacterial lysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622217      PMCID: PMC1459742          DOI: 10.1128/IAI.74.5.2803-2808.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B.

Authors:  G Vidarsson; W L van Der Pol; J M van Den Elsen; H Vilé; M Jansen; J Duijs; H C Morton; E Boel; M R Daha; B Corthésy; J G van De Winkel
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

2.  Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model.

Authors:  M Toropainen; L Saarinen; P van der Ley; B Kuipers; H Käyhty
Journal:  Microb Pathog       Date:  2001-03       Impact factor: 3.738

3.  Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes.

Authors:  A K Lehmann; A R Gorringe; K M Reddin; K West; I Smith; A Halstensen
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine.

Authors:  Jo Anne Welsch; Raffaella Rossi; Maurizio Comanducci; Dan M Granoff
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule.

Authors:  E J Brown; K A Joiner; R M Cole; M Berger
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

7.  Hereditary C6 deficiency in a strain of PVG/c rats.

Authors:  P L Leenaerts; R K Stad; B M Hall; B J Van Damme; Y Vanrenterghem; M R Daha
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

8.  Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.

Authors:  Jo Anne Welsch; Gregory R Moe; Raffaella Rossi; Jeannette Adu-Bobie; Rino Rappuoli; Dan M Granoff
Journal:  J Infect Dis       Date:  2003-11-19       Impact factor: 5.226

9.  PorA variable regions of Neisseria meningitidis.

Authors:  Joanne E Russell; Keith A Jolley; Ian M Feavers; Martin C J Maiden; Janet Suker
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  9 in total

1.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates.

Authors:  Maritza Lienlaf; Juan Pablo Morales; María Inés Díaz; Rodrigo Díaz; Elsa Bruce; Freddy Siegel; Gloria León; Paul R Harris; Alejandro Venegas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

3.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 4.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

5.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

6.  Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Authors:  Joyce S Plested; Jo Anne Welsch; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

7.  Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Authors:  Andrew R Gorringe; Stephen Taylor; Charlotte Brookes; Mary Matheson; Michelle Finney; Moyra Kerr; Michael Hudson; Jamie Findlow; Ray Borrow; Nick Andrews; George Kafatos; Cariad M Evans; Robert C Read
Journal:  Clin Vaccine Immunol       Date:  2009-06-24

8.  Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei.

Authors:  Bhavani V Peddayelachagiri; Soumya Paul; Shivakiran S Makam; Radhika M Urs; Joseph J Kingston; Urmil Tuteja; Murali H Sripathy; Harsh V Batra
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

9.  Complement C6 deficiency exacerbates pathophysiology after spinal cord injury.

Authors:  Diane Su; Mitra J Hooshmand; Manuel D Galvan; Rebecca A Nishi; Brian J Cummings; Aileen J Anderson
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.